BioRestorative Therapies (BRTX)
Develops autologous cell therapies and cell-secretome cosmetics for spine and metabolic applications.
Something off on this page? Send us feedback.
Develops an investigational autologous cell therapy for chronic lumbar disc disease and a preclinical metabolic platform, while supplying a cell-secretome cosmetics product and earning licensing royalties. Operations combine internal cell manufacturing with outside trial partners and a private-label distribution relationship.
Develops BRTX-100, an investigational autologous cell therapy for chronic lumbar disc disease, alongside the preclinical ThermoStem metabolic platform. BRTX-100 uses a patient's bone-marrow mesenchymal stem cells, cultured under low-oxygen conditions and injected into damaged intervertebral discs.
Operates research and clinical manufacturing in Melville, New York, processing its lead therapy and making a cell-secretome cosmetic product supplied through Cartessa's Chronos ExoCR private-label channel. It also earns royalties from sublicensed disc and spine intellectual property.
Progress depends on FDA authorization, trial execution by outside clinical partners, licensed disc and spine technology, patient-specific manufacturing, and financing. The lead study remains blinded, with no efficacy results reported.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Mar 31, 2026Cash & short-term investments $3.6M · Total debt $34.5K · Total assets $4.6M · Shareholders' equity $3.0M
- Revenue
- $23.2K
- Operating income
- −$3.4M
- Net income
- −$2.2M
No dividends on record.
| Institutions | 10.46% | 133.3K shares | |
|---|---|---|---|
| 19 holders · as of Jun 30, 2026 | |||
| Insiders | 2.49% | 31.7K shares | |
| 2 holders · as of Oct 20, 2025 | |||
| Other | 87.05% | 1.11M shares | |
| remainder | |||
1.27M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Jane Street Group, LLCInstitution | 3.15% | 803,513 | as of Jun 30, 2026 |
HRT Financial LPInstitution | 2.79% | 710,590 | as of Jun 30, 2026 |
Dale BroadrickInsider10 percent owner | 1.75% | 22,297 | filed Nov 5, 2024 |
XTX Topco LtdInstitution | 1.12% | 286,504 | as of Jun 30, 2026 |
Citadel Advisors LLCInstitution | 1.07% | 273,304 | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Mesoblast (ADR)
Intradiscal cell-therapy rival in chronic lumbar disc disease.
- Novo Nordisk (ADR)
Marketed GLP-1 drugs dominate obesity and type 2 diabetes care.
- Eli Lilly
Zepbound and Mounjaro address the same metabolic populations.
- Viking Therapeutics
Late-stage obesity candidate targets the future metabolic market.
- Altimmune
Dual GLP-1/glucagon candidate overlaps prospective obesity care.
- Sanofi (ADR)
Established diabetes therapies overlap prospective metabolic indications.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| BioRestorative Therapies | $2.81 | +3.51% | $3.7M | — | — | 10.5 | −7.3% |
| Mesoblast (ADR) | $15.89 | +2.65% | $2.01B | — | — | 16.6 | +391.8% |
| Novo Nordisk (ADR) | $39.33 | −1.18% | $176.83B | 9.9 | 16.2 | 3.5 | +1.3% |
| Eli Lilly | $1,171.33 | +0.55% | $1.10T | 39.1 | 28.6 | 13.8 | +47.7% |
| Viking Therapeutics | $39.72 | +31.92% | $3.51B | — | — | — | — |
| Altimmune | $3.35 | +2.29% | $635.9M | — | — | 20,513.9 | +820.0% |
| Sanofi (ADR) | $42.51 | +0.01% | $102.05B | 75.6 | — | 1.8 | +11.2% |
| Median | 39.1 | 22.4 | 13.8 | +47.7% |